A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1995-11, Vol.72 (5), p.1256-1258 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1258 |
|---|---|
| container_issue | 5 |
| container_start_page | 1256 |
| container_title | British journal of cancer |
| container_volume | 72 |
| creator | IAFFAIOLI, R. V TORTORIELLO, A ANTONELLI, B VALLEFUOCO, V MOSELLA, G CAPONIGRO, F FACCHINI, G SANTANGELO, M DE SENA, G GESUE', G BUCCI, L SCARAMELLINO, G ANASTASIO, E FINIZIO, A |
| description | Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation. |
| doi_str_mv | 10.1038/bjc.1995.496 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16466117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-1265cc12f0783bdc30db14d80cc464cb3c7d3de623dd3a9cf7566b501e3b21d23</originalsourceid><addsrcrecordid>eNpVkUtr3DAUhUVpSCZpd90WtChdxRM9LMneFEJok4FAN81aXD3cOHikiSQP5N9XZoahWYmr83HO5R6EvlCypoR3N-bFrmnfi3Xbyw9oRQVnDe2Y-ohWhBDVkJ6RC3SZ80sde9Kpc3SuhFKt6lbI3uLdM2SPNxucy-zecBywhWTiboIyBgzB4f0YYvKTGYPHkHH2NgbXTMtYkoey9aHgISYMbg_BeodN_c6lGtUpfUJnA0zZfz6-V-jp188_dw_N4-_7zd3tY2Nb2ZaGMimspWwgquPGWU6coa3riF10a7hVjjsvGXeOQ28HJaQ0glDPDaOO8Sv04-C7m83WO1u3SjDpXRq3kN50hFG_V8L4rP_GvWaE816oavD9aJDi6-xz0dsxWz9NEHycs6aylZLSBbw-gDbFnJMfTiGU6KUUXUvRSym6llLxr_8vdoKPLVT921GHbGEaUj3bmE8Y6_pOcFExfMAClDn5k16zlqgl6R_hIqGy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16466117</pqid></control><display><type>article</type><title>A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><creator>IAFFAIOLI, R. V ; TORTORIELLO, A ; ANTONELLI, B ; VALLEFUOCO, V ; MOSELLA, G ; CAPONIGRO, F ; FACCHINI, G ; SANTANGELO, M ; DE SENA, G ; GESUE', G ; BUCCI, L ; SCARAMELLINO, G ; ANASTASIO, E ; FINIZIO, A</creator><creatorcontrib>IAFFAIOLI, R. V ; TORTORIELLO, A ; ANTONELLI, B ; VALLEFUOCO, V ; MOSELLA, G ; CAPONIGRO, F ; FACCHINI, G ; SANTANGELO, M ; DE SENA, G ; GESUE', G ; BUCCI, L ; SCARAMELLINO, G ; ANASTASIO, E ; FINIZIO, A</creatorcontrib><description>Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1995.496</identifier><identifier>PMID: 7577478</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adult ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Carboplatin - administration & dosage ; Carboplatin - adverse effects ; Chemotherapy ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Humans ; Leukopenia - chemically induced ; Medical sciences ; Neoplasm Metastasis ; Pharmacology. Drug treatments ; Phlebitis - chemically induced ; Remission Induction ; Salvage Therapy ; Treatment Outcome ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - analogs & derivatives ; Vinorelbine</subject><ispartof>British journal of cancer, 1995-11, Vol.72 (5), p.1256-1258</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-1265cc12f0783bdc30db14d80cc464cb3c7d3de623dd3a9cf7566b501e3b21d23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033957/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033957/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,2728,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2898535$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7577478$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IAFFAIOLI, R. V</creatorcontrib><creatorcontrib>TORTORIELLO, A</creatorcontrib><creatorcontrib>ANTONELLI, B</creatorcontrib><creatorcontrib>VALLEFUOCO, V</creatorcontrib><creatorcontrib>MOSELLA, G</creatorcontrib><creatorcontrib>CAPONIGRO, F</creatorcontrib><creatorcontrib>FACCHINI, G</creatorcontrib><creatorcontrib>SANTANGELO, M</creatorcontrib><creatorcontrib>DE SENA, G</creatorcontrib><creatorcontrib>GESUE', G</creatorcontrib><creatorcontrib>BUCCI, L</creatorcontrib><creatorcontrib>SCARAMELLINO, G</creatorcontrib><creatorcontrib>ANASTASIO, E</creatorcontrib><creatorcontrib>FINIZIO, A</creatorcontrib><title>A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - adverse effects</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Leukopenia - chemically induced</subject><subject>Medical sciences</subject><subject>Neoplasm Metastasis</subject><subject>Pharmacology. Drug treatments</subject><subject>Phlebitis - chemically induced</subject><subject>Remission Induction</subject><subject>Salvage Therapy</subject><subject>Treatment Outcome</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinorelbine</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtr3DAUhUVpSCZpd90WtChdxRM9LMneFEJok4FAN81aXD3cOHikiSQP5N9XZoahWYmr83HO5R6EvlCypoR3N-bFrmnfi3Xbyw9oRQVnDe2Y-ohWhBDVkJ6RC3SZ80sde9Kpc3SuhFKt6lbI3uLdM2SPNxucy-zecBywhWTiboIyBgzB4f0YYvKTGYPHkHH2NgbXTMtYkoey9aHgISYMbg_BeodN_c6lGtUpfUJnA0zZfz6-V-jp188_dw_N4-_7zd3tY2Nb2ZaGMimspWwgquPGWU6coa3riF10a7hVjjsvGXeOQ28HJaQ0glDPDaOO8Sv04-C7m83WO1u3SjDpXRq3kN50hFG_V8L4rP_GvWaE816oavD9aJDi6-xz0dsxWz9NEHycs6aylZLSBbw-gDbFnJMfTiGU6KUUXUvRSym6llLxr_8vdoKPLVT921GHbGEaUj3bmE8Y6_pOcFExfMAClDn5k16zlqgl6R_hIqGy</recordid><startdate>19951101</startdate><enddate>19951101</enddate><creator>IAFFAIOLI, R. V</creator><creator>TORTORIELLO, A</creator><creator>ANTONELLI, B</creator><creator>VALLEFUOCO, V</creator><creator>MOSELLA, G</creator><creator>CAPONIGRO, F</creator><creator>FACCHINI, G</creator><creator>SANTANGELO, M</creator><creator>DE SENA, G</creator><creator>GESUE', G</creator><creator>BUCCI, L</creator><creator>SCARAMELLINO, G</creator><creator>ANASTASIO, E</creator><creator>FINIZIO, A</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>19951101</creationdate><title>A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer</title><author>IAFFAIOLI, R. V ; TORTORIELLO, A ; ANTONELLI, B ; VALLEFUOCO, V ; MOSELLA, G ; CAPONIGRO, F ; FACCHINI, G ; SANTANGELO, M ; DE SENA, G ; GESUE', G ; BUCCI, L ; SCARAMELLINO, G ; ANASTASIO, E ; FINIZIO, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-1265cc12f0783bdc30db14d80cc464cb3c7d3de623dd3a9cf7566b501e3b21d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - adverse effects</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Leukopenia - chemically induced</topic><topic>Medical sciences</topic><topic>Neoplasm Metastasis</topic><topic>Pharmacology. Drug treatments</topic><topic>Phlebitis - chemically induced</topic><topic>Remission Induction</topic><topic>Salvage Therapy</topic><topic>Treatment Outcome</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinorelbine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IAFFAIOLI, R. V</creatorcontrib><creatorcontrib>TORTORIELLO, A</creatorcontrib><creatorcontrib>ANTONELLI, B</creatorcontrib><creatorcontrib>VALLEFUOCO, V</creatorcontrib><creatorcontrib>MOSELLA, G</creatorcontrib><creatorcontrib>CAPONIGRO, F</creatorcontrib><creatorcontrib>FACCHINI, G</creatorcontrib><creatorcontrib>SANTANGELO, M</creatorcontrib><creatorcontrib>DE SENA, G</creatorcontrib><creatorcontrib>GESUE', G</creatorcontrib><creatorcontrib>BUCCI, L</creatorcontrib><creatorcontrib>SCARAMELLINO, G</creatorcontrib><creatorcontrib>ANASTASIO, E</creatorcontrib><creatorcontrib>FINIZIO, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IAFFAIOLI, R. V</au><au>TORTORIELLO, A</au><au>ANTONELLI, B</au><au>VALLEFUOCO, V</au><au>MOSELLA, G</au><au>CAPONIGRO, F</au><au>FACCHINI, G</au><au>SANTANGELO, M</au><au>DE SENA, G</au><au>GESUE', G</au><au>BUCCI, L</au><au>SCARAMELLINO, G</au><au>ANASTASIO, E</au><au>FINIZIO, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1995-11-01</date><risdate>1995</risdate><volume>72</volume><issue>5</issue><spage>1256</spage><epage>1258</epage><pages>1256-1258</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>7577478</pmid><doi>10.1038/bjc.1995.496</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1995-11, Vol.72 (5), p.1256-1258 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2033957 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; PubMed Central |
| subjects | Adult Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Female Follow-Up Studies Granulocyte Colony-Stimulating Factor - therapeutic use Humans Leukopenia - chemically induced Medical sciences Neoplasm Metastasis Pharmacology. Drug treatments Phlebitis - chemically induced Remission Induction Salvage Therapy Treatment Outcome Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives Vinorelbine |
| title | A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T09%3A02%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20carboplatin%20and%20vinorelbine%20as%20second-line%20treatment%20for%20advanced%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=IAFFAIOLI,%20R.%20V&rft.date=1995-11-01&rft.volume=72&rft.issue=5&rft.spage=1256&rft.epage=1258&rft.pages=1256-1258&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1995.496&rft_dat=%3Cproquest_pubme%3E16466117%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16466117&rft_id=info:pmid/7577478&rfr_iscdi=true |